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Abstract
Background: Analysis of high microsatellite instability (MSI-H) phenotype in colorectal carcinoma (CRC) is important
for evaluating prognosis and choosing a proper adjuvant therapy. Although the conventional MSI analysis methods
such as polymerase chain reaction (PCR) fragment analysis and immunohistochemistry (IHC) show high specificity
and sensitivity, there are substantial barriers to their use.
Methods: In this study, we analyzed the MSI detection performance of three molecular tests and IHC. For the
molecular tests, we included a recently developed peptide nucleic acid probe (PNA)-mediated real-time PCR-based
method using five quasi-monomorphic mononucleotide repeat markers (PNA method) and two conventional PCR
fragment analysis methods using NCI markers (NCI method) or five quasi-monomorphic mononucleotide repeat
markers (MNR method). IHC analysis was performed with four mismatch repair proteins. The performance of each
method was validated in 166 CRC patient samples, which consisted of 76 MSI-H and 90 microsatellite stable (MSS)
CRCs previously diagnosed by NCI method.
Results: Of the 166 CRCs, 76 MSI-H and 90 MSS CRCs were determined by PNA method. On the other hand, 75
MSI-H and 91 MSS CRCs were commonly determined by IHC and MNR methods. Based on the originally diagnosed
MSI status, PNA showed 100% sensitivity and 100% specificity while IHC and MNR showed 98.68% sensitivity and
100% specificity. When we analyzed the maximum sensitivity of MNR and PNA method, which used the same five
markers, PNA method could detect alterations in all five mononucleotide repeat markers in samples containing
down to 5% MSI-H DNAs, whereas MNR required at least 20% MSI-H DNAs to achieve the same performance.
Conclusions: Based on these findings, we suggest that PNA method can be used as a practical laboratory test for
the diagnosis of MSI.
Keywords: Microsatellite instability, Colorectal cancer, Real-time polymerase chain reaction, Peptide nucleic acid
probe and immunohistochemistry
Background
The molecular pathogenesis of colorectal carcinoma
(CRC) is well understood in comparison with other can-
cers. The development of a broad range of CRCs can be
explained by the multistep carcinogenesis model and
high microsatellite instability (MSI-H) resulting from
deficiencies of the mismatch repair (MMR) gene set,
which consists of MSH2, MLH1, MSH6, and PMS2. The
MSI-H phenotype is found in both hereditary
non-polyposis colorectal cancer (HNPCC) with germline
mutation in MMR gene set (3%) and sporadic CRCs
with CpG island methylator phenotype in MMR gene
set (12%), together which account for approximately
15% of all CRCs [1]. Regardless of the origin (hereditary
or sporadic) or type of mutation, MSI-H quantitatively
or qualitatively alters the expression of numerous genes
harboring nucleotide repeats, such as transforming
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growth factor-β receptor 2, TCF-4, BAX, MLH3, and
RAD50, which may contribute to the development of
CRCs, increased neoantigen production, and increased
sensitivity to immunotherapy [2–5].
In addition to CRCs, MSI-H has frequently been re-
ported in other types of cancers including endometrial
and gastric cancer and is expected to play direct or in-
direct roles in the development of these cancers. A re-
cent comprehensive MSI screening study showed that
the degree of MSI positively correlates with the survival
of patients with various cancers [6]. Thus, precise and
rapid detection of MSI status has become more crucial
for both research and clinical practice. There are several
laboratory tests for determining MSI status, including
polymerase chain reaction (PCR)-based analysis of MSI
markers and immunohistochemistry (IHC) staining of
MMR proteins [7]. However, conventional PCR-based
MSI interrogation requires complicated steps and add-
itional equipment and shows low sensitivity for samples
with a small proportion of tumor cells. On the other
hand, IHC analysis requires pathologists, and interpret-
ation criteria can be subjective and affected by technical
factors. Therefore, a more accurate and simple MSI test
strategy is needed.
We aimed to evaluate the MSI detection performance
of various MSI detection methods, including the follow-
ing: a recently developed peptide nucleotide acid probe
(PNA)-mediated real-time PCR-based MSI test using
five quasi-monomorphic mononucleotide repeat markers
(PNA method) and two conventional PCR fragment ana-
lysis methods, PCR fragment analysis with two mononu-
cleotide and three dinucleotide repeat markers proposed
by the National Cancer Institute (NCI method) [8], and
PCR fragment analysis with the same mononucleotide
repeat (MNR) markers as PNA method (MNR method)
as well as IHC method. Each MSI detection method was
validated in 166 CRCs and paired normal specimens. In
this study, we provided practical data for proper selec-
tion and application of MSI detection methods.
Methods
Cell lines and patient tissue samples
For testing the sensitivity of PNA (U-TOP™ MSI Detec-
tion Kit) and MNR (Promega MSI Analysis System Kit),
HeLa (microsatellite stable, MSS) and SNU-638 (MSI-H)
cell lines were used. HeLa cells and SNU-638 cells were
cultured with DMEM and RPMI1640 medium, respect-
ively. Each medium was supplemented with 10% FBS
(Invitrogen Life Technologies, Carlsbad, CA, USA) and
1% penicillin/streptomycin.
Formalin-fixed paraffin-embedded (FFPE) tissue sam-
ples were collected from 2263 patients with CRCs who
visited Severance Hospital between January 2005 and
December 2015. A total of 166 CRCs (76 diagnosed as
MSI-H and 90 diagnosed as MSS) and matched
non-neoplastic colon mucosal tissues were randomly se-
lected for this study. MSI status was previously analyzed
using the NCI method. The specimens were obtained
from the archives of the Department of Pathology, Yon-
sei University, Seoul, Korea and the Liver Cancer Speci-
men Bank of the National Research Resource Bank
Program of the Korean Science and Engineering Foun-
dation, Ministry of Science and Technology.
PNA probe-mediated real-time PCR sensing for detection
of MSI status
We tested the performance of the PNA method in de-
tecting MSI status in colon cancer samples using gen-
omic DNA samples (gDNAs) extracted from FFPE CRCs
and matched normal tissues. gDNA was isolated accord-
ing to the manufacturer’s instructions (QIAamp DNA
FFPE Tissue Kit, Qiagen, Venlo, Netherlands; Maxwell®
16 FFPE Purification Kit for DNA, Promega). Both qual-
ity and quantity of extracted genomic DNA samples
were evaluated by using the Nanodrop (Thermo Wal-
tham, MA, USA) and subsequent gel electrophoresis. In
PNA method, wild type PNA probe perfectly hybridized
with wild type allele, while partial or mismatch
hybridization caused melting temperature of PNA probe
to be lower than that of perfectly matched probe. At de-
naturation temperature, PNA probe was subject to fluor-
escence quenching by random coiling, and this
quenching temperature was analyzed by real-time PCR
machine [9, 10].
To assess MSI status with PNA method, U-TOP™ MSI
Detection Kit was purchased from SeaSun Biomaterials
(Daejeon, Korea). This commercially available product
employed five MSI marker genes (NR21, NR24, NR27,
BAT25, and BAT26). A 20-μl mixture composed of
gDNA sample (3 μl), 2 × qPCR Premix (10 μl), and
dual-labeled (fluorescence and quencher) PNA probes
for NR21, NR24, and BAT26 (MSI Marker A; 7 μl), as
well as another 20-μl mixture composed of gDNA sam-
ple (3 μl), 2 × qPCR Premix (10 μl) and dual-labeled PNA
probes for BAT25 and NR27 (MSI Marker B; 7 μl). The
qPCR premix contained dNTP and DNA Taq polymer-
ase, as well as Uracil DNA Glycosylase (UDG). Each
PNA probe was fluorescently labeled with Texas-Red,
Hexachloro-fluorescein, or Fluorescein amidite. Two in-
dividual real-time PCR reactions were performed for
each normal and cancer sample using a CFX96 PCR ma-
chine (Bio-Rad, Hercules, CA, USA). PCR reaction steps
consisted of amplification and subsequent melting point
analysis. The amplification condition was 50 °C for 5
min, 95 °C for 10 min, and 60 cycles of 95 °C for 30 s, 65
°C for 30 s, 55 °C for 30 s, and 57 °C for 45 s. The initial
incubation at 50 °C for 5 min was required to activate
Uracil DNA Glycosylase and prevent possible carryover
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contamination. In 60 cycles of PCR, four different tem-
peratures and respective optimal times were required.
The main purpose of using these conditions was to en-
sure specific binding of PNA probes to their target MSI
marker. In detail, 95 °C for 30 s was for denaturation of
template DNAs, 65 °C for 30 s was for binding of PNA
probes to their target MSI markers, 55 °C for 30 s was
for annealing temperature of primers, and 57 °C for 45 s
was for elongation of a polymerase. The melting point
analysis condition was 10 min at 95 °C for denaturation
and touchdown PCR (90 °C to 45 °C, decreasing 1 °C per
cycle). Fluorescence was measured for 10 s at each cycle
of touchdown PCR. Obtained melting peaks were ana-
lyzed to detect alterations in the five MSI marker genes.
A CRC sample was considered to be unstable in a MSI
marker gene when a > 3 °C melting temperature differ-
ence between a CRC and the normal sample was ob-
served. For the analysis of minimal base pair alteration
that PNA method can detect, we used artificially synthe-
sized oligo targets using either deletions or insertions
(Macrogen, Seoul, Korea).
PCR fragment analysis
For NCI method, five microsatellite loci (BAT-25,
BAT-26, D2S123, D5S346, and D17S250) recommended
by the 1997 NCI-sponsored MSI workshop were ampli-
fied in a single multiplex PCR reaction. PCR products
were analyzed by capillary electrophoresis. For interpret-
ation, instability at more than one locus was defined as
MSI-H, instability at a single locus was defined as low
MSI (MSI-L), and no instability at any locus was defined
as MSS. For MNR method, amplification of five MSI
markers (NR21, NR24, BAT26, BAT25, and NR27) was
performed using gDNAs extracted from CRCs and
matched normal samples. PCR reactions were performed
with the MSI Analysis System Kit referring to the MSI
Analysis System Version 1.2 protocol. This kit was pur-
chased from Promega (Madison, WI, USA). Amplified
PCR products were purified using a PCR clean-up kit
(Macherey-Nagel, Düren, Germany), and the size of PCR
amplicons was analyzed using an ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). Based on data obtained from the sequencer, MSI
status was determined by random experts (Macrogen).
Immunohistochemistry
Paraffin-embedded tissue blocks were cut into 4-μm sec-
tions. IHC analysis was performed using a Ventana XT au-
tomated stainer (Ventana Corporation, Tucson, AZ, USA)
with antibodies against the following: MutL homolog 1
(MLH1, diluted 1:50, BD Biosciences, San Jose, CA, USA),
MutS homolog 2 (MSH2, diluted 1:200, BD Biosciences),
MutS homolog 6 (MSH6, diluted 1:100, Cell Marque,
Rocklin, CA, USA), and PMS1 homolog 2 (PMS2, diluted
1:40, Cell Marque). Positive internal controls including
stromal cells and lymphoid cells were confirmed, and the
percentage of nuclear expression was measured.
Statistical analysis
To calculate the diagnostic sensitivity and specificity of
each MSI test, McNemar’s tests were performed. The sen-
sitivity (%) of each MSI analysis method was calculated as
follows: 100 × true positives/(true positives + false nega-
tives), where true positives and false negatives were de-
fined according to MSI status originally diagnosed by NCI
method. The specificity (%) of PNA method was calcu-
lated as follows: 100 × true negatives/(false positives + true
negatives), where true negatives and false positives were
defined according to MSI status originally diagnosed by
NCI method.
To determine the sample number required for this
study, we performed non-inferiority test at a significance
level of 0.05 and a statistical power of 80%. The average
of positive predictive value (PPV) and negative predictive
value (NPV) were obtained from 10 reference articles
[11–20], where methods using microsatellite instability
testing or real-time PCR were compared to immunohis-
tochemistry for detecting mutations of MLH1, MSH2,
MSH6, and PMS2 or other human genes. The average
PPV and NPV were 91.1 and 93.6%, respectively, and the
differences from lower margin of 95% confidence inter-
vals (CI; δ, non-inferiority margin) were − 5.49% and −
4.3%, respectively. Based on reference articles, the sizes
of MSI-H and MSS samples were calculated using the
equation below, considering a 10% dropout rate.
N ¼ Zα=2 þ Zβ
 2
P 1−Pð Þ
δ− P−P0j jð Þ2
P = average PPV and NPV values from reference
articles; P0= expected PPV and NPV for this study
(equivalence); Zα/2=1.96; Zβ = 0.842.
Based on the calculation above, we came to the con-
clusion that more than 68 MSI-H and 89 MSS CRC
samples were required for this study, and performed
MSI analysis in 76 MSI-H and 90 MSS CRC samples.
To analyze clinicopathological parameters, statistical
analyses were performed using SPSS software, version
21.0.0.0 for Windows (IBM., Armonk, NY, USA).
Mann-Whitney tests, Student’s t-tests, Fisher’s exact
tests, or χ2 tests were used depending on the purpose;
P-values < 0.05 were considered statistically significant.
Results
Determination of MSI status by three conventional MSI
detection methods
We randomly collected 166 cases from 2263 CRCs that
had undergone MSI status analysis with variable
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methods from January 2005 to December 2015. The
NCI analysis results of the 166 cases were also collected.
Seventy-six cases were previously diagnosed as MSI-H
and 90 cases as MSS or MSI-L.
To test the performance of conventional MSI detection
methods, we conducted MNR method with five
quasi-monomorphic mononucleotide markers (Promega
MSI Analysis System Kit) and IHC with four MMR pro-
teins (MLH1, MSH2, MSH6, and PMS2). MSI analysis re-
sults determined by each method are summarized in
Additional file 1: Table S1. Among the 76 MSI-H cases, 74
cases showed MSI-H in all three conventional MSI tests.
Case no. 1 was diagnosed as MSI-H by NCI and IHC but
was diagnosed as MSI-L by MNR. Case no. 20 was
diagnosed as MSI-H by NCI and MNR, but no loss of pro-
tein expression was detected by IHC (Additional file 1:
Table S1 and Additional file 2: Figure S1).
Diagnostic sensitivity and specificity of three MSI test
methods
To assess the clinical sensitivity and specificity of each
MSI test, McNemar’s tests were performed by compar-
ing the MSI analysis results of IHC, MNR, and PNA
methods with the MSI status originally diagnosed by
NCI method in the 166 CRCs (Table 1). The clinical
sensitivity and specificity of PNA method were 100%
(95% confidence interval (CI): 95.2–100%) and 100%
(95% CI: 95.9–100%), respectively. On the other hand,
the clinical sensitivity and specificity of MNR and IHC
methods were 98.68% (95% CI: 92.9–99.8%) and 100%
(95% CI: 95.9–100%), respectively.
Next, we evaluated the maximum sensitivity of the
MNR and PNA methods, which used the same five MSI
markers. To do so, mixed samples of gDNAs extracted
from HeLa cells (microsatellite stable, MSS) and
SNU-638 cells (MSI-H) were used, and MNR and PNA
analyses were performed with different proportions (0, 1,
5, 10, 20, 40, and 100%) of MSI-H variant. MNR analysis
showed that SNU-638 cells harbored 7-, 8-, 8-, 12-, and
10-base deletion mutations in NR21, NR24, BAT25,
BAT26, and NR27, respectively. PNA method was cap-
able of detecting alterations in all five MSI markers in
the mixed samples, including down to 5% MSI-H vari-
ant, whereas MNR method required a sample containing
up to 20% MSI-H variant to detect alterations in all five
MSI markers. PNA method was further capable of de-
tecting 1% MSI-H variant in NR21 and BAT25 markers
(Fig. 1 and Additional file 3: Table S2). The repeatedly
performed experiments using PNA method provided
consistent and reproducible results, irrespective of the
type of MSI markers and portion of MSI variants. To
evaluate the qualitative performance of PNA method, we
determined the minimum alteration number in each
MSI marker that PNA method can detect, using artifi-
cially synthesized oligo targets containing one or
two-base deletion mutations and one or two-base inser-
tion mutations. The samples used in this experiment
were composed of 100% MSI variant. Oligo targets con-
taining insertion mutations were included because
mononucleotide microsatellites often exhibit insertion
mutations. The analysis result showed that PNA method
clearly detected up to two-base deletion and one-base
insertion mutations of the five MSI markers (Additional
file 2: Figure S2). Then, we performed PNA analysis
using titrated samples with MSI variants containing a
two-base deletion or one-base insertion to evaluate the
quantitative performance of PNA method. The analysis
results showed that PNA method clearly detected a
two-base deletion or one-base insertion of the five MSI
markers in samples containing more than 5% MSI-H
variants (Fig. 2).
Determination of MSI status by the PNA probe-mediated
melting point analysis
MSI status was determined by PNA method, which was a
recently developed real-time PCR based method. The re-
sults of PNA method showed sharp melting curves highly
specific to each cancer sample as compared with paired
normal samples (Fig. 3, left panel). MNR method also
showed readable size differences between cancer and
paired normal samples (Fig. 3, right panel). Samples with
alterations in more than one MSI marker were deter-
mined as MSI-H, whereas samples with an alteration in a
single MSI marker or no alteration were determined as
MSI-L or MSS, respectively (Fig. 3 and Additional file 2:
Figure S3). MSI-L and MSS were grouped together for
statistical analysis based on a previous report of no
Table 1 MSI analysis results of NCI, PNA, MNR, and IHC
methods for 166 CRCs
Total Sample (n = 166) MSI status Sum
MSI-H
(n = 76)
MSS
(n = 90)
NCI method MSI-H 76 0 76
MSS 0 90 90
Sum 76 90 166
PNA method MSI-H 76 0 76
(U-TOP™ MSI Detection Kit) MSS 0 90 90
Sum 76 90 166
MNR method MSI-H 75 0 75
(Promega MSI analysis system kit) MSS 1 90 91
Sum 76 90 166
IHC method MSI-H 75 0 75
MSS 1 90 91
Sum 76 90 166
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significant clinicopathological or molecular differences be-
tween MSI-L and MSS CRCs [21]. MSI analysis using
PNA method indicated that 76 samples were MSI-H and
the remaining 90 were MSS, which was the same result as
that of NCI analysis. A comparison of instability in each
MSI marker between PNA and MNR method showed sig-
nificant difference in NR24, with PNA having higher de-
tection rates (Additional file 3: Table S3). We also note
that one case (Case no. 1) was determined as MSI-L by
MNR but was determined as MSI-H by NCI, IHC, and
PNA methods (Additional file 1: Table S1).
Clinicopathologic findings of sporadic and hereditary
MSI-H CRCs
We observed that MSI-H and MSS CRCs showed distinct-
ive clinicopathologic characteristics, as previously re-
ported [2]. Compared with MSS CRCs, MSI-H CRCs
were more frequently found in the right colon and showed
larger and exophytic features. Elevated pre-operative car-
cinoembryonic antigen (CEA) level and advanced T stage
were noted in MSS CRCs. Mucinous adenocarcinoma and
signet ring cell carcinoma were observed more often in
MSI-H CRCs than in MSS CRCs. Patients with MSI-H
Fig. 1 Maximum sensitivity evaluation of PNA and MNR method. The maximum sensitivity of PNA and MNR methods was evaluated using mixed
samples of genomic DNA samples obtained from HeLa (MSS) and SNU-638 (MSI-H) cells. a PNA method was capable of detecting alteration in all
five MSI marker genes in samples containing down to 5% MSI-H variant. b MNR method required at least 20% MSI-H variant in samples to detect
alteration in all five MSI marker genes
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CRCs were younger on average than patients with MSS
CRCs (Additional file 3: Table S4).
Among the 166 CRCs, 155 cases did not satisfy
Amsterdam II and Revised Bethesda criteria, which
allowed us to clinically define these cases as sporadic
CRCs. Eleven cases showed clinical features of HNPCC
as suggested by Amsterdam II or Revised Bethesda cri-
teria. Analysis of these 11 clinically diagnosed HNPCC
cases by NCI, MNR, IHC, and PNA methods showed
that two cases were determined as MSS in all four tests,
indicating that these two cases can be considered as fa-
milial colorectal cancer type X. In the remaining nine
cases, MSI-H was determined by all four tests and muta-
tions in MLH1 or MSH2 were detected (data not
shown), which leads us to consider the nine cases are
Lynch syndrome. Consequently, nine and 67 cases were
classified as MSI-H CRCs associated with Lynch syn-
drome and sporadic MSI-H CRCs, respectively. Whereas
most clinicopathologic characteristics of the nine cases
with Lynch syndrome and 67 sporadic MSI-H CRC cases
were similar, some parameters showed significant differ-
ences (Additional file 3: Table S5). Patients in the Lynch
syndrome group were younger on average than patients
in the sporadic CRC group. Also, mean tumor size was
smaller in the Lynch syndrome group, perhaps because
the features of hereditary CRCs, such as family history
and early symptoms, may lead to early health check-ups
and the detection of smaller tumors. There were no dif-
ferences in other parameters such as MMR protein ex-
pression status, tumor location, pre-operative CEA level,
Fig. 2 Evaluation of maximum sensitivity of PNA method using oligo targets containing minimal base pair alteration. a and b PNA analysis was
performed using oligo samples containing different portions of MSI variants with two-base deletion or one-base insertion. PNA method clearly
detected two-base deletion and one-base insertion in all five MSI markers in samples containing 5% or more MSI-H variant
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gross type, histologic diagnosis, T stage, lymphovascular
invasion, mucin formation, Crohn-like reaction, or tumor
budding.
Diagnostic value of IHC using antibodies against four
MMR proteins to determine MSI status
Next, we performed IHC analysis of four MMR proteins
in the 166 CRCs to determine MSI status. MSI-H was
defined as the loss of expression of at least one MMR
protein in more than 95% of tumor cells. By this criter-
ion, we detected MSI-H in 75 out of 76 samples (98.7%).
The percentage of nuclear expression of MMR proteins
was also measured in all cases, and MSI status was fur-
ther analyzed according to various cut-off values of loss
of MMR protein expression (Additional file 3: Table S6).
When we defined MMR deficit as a complete loss of nu-
clear staining, we observed 84.21% concordance with the
originally diagnosed MSI status using two antibodies
against MLH1 and MSH2, 73.68% concordance with two
antibodies against PMS2 and MSH6, and 90.79%
concordance with all four antibodies against MLH1,
MSH2, PMS2, and MSH6. When we defined MMR def-
icit as < 1% nuclear staining, we observed 84.21% con-
cordance with MLH1 and MSH2 antibodies, 89.47%
concordance with PMS2 and MSH6 antibodies, and
96.05% with all four antibodies. When we defined MMR
as < 5% nuclear staining, we observed 90.79% concord-
ance with MLH1 and MSH2 antibodies and 98.68%
concordance with PMS2 and MSH6 antibodies or all
four antibodies. Overall, therefore, an IHC criterion of
95% was the best match to the original MSI diagnosis
results.
Discussion
The determination of MSI status is important because
CRCs with MSI-H show distinguishing clinicopathologic
characteristics and require optimized treatment [22, 23].
IHC for MMR proteins can effectively identify CRCs with
a MSI-H subtype and provides indirect information about
the affected MMR pathway. IHC is a relatively quick and
simple assay for determining MSI status by evaluating the
protein expression of four MMR genes: MLH1, MSH2,
MSH6, and PMS2. MLH1 forms a functional complex
with PMS2, and MSH2 forms a functional complex with
MSH6. Because MLH1 is responsible for the stability of
PMS2, the combined loss of PMS2 and MLH1 suggests
that MLH1 is defective. Similarly, the combined loss of
MSH2 and MSH6 suggests a defect within MSH2. Our
finding that the co-loss of MLH1/PMS2 or MSH2/MSH6
predominantly occurred in MSI-H CRC samples further
supports a relationship among MMR proteins.
We also observed variable MMR expression patterns
such as loss of a single MMR marker, loss of MLH1 to-
gether with MSH2 and MSH6, loss of MSH6 together
with MLH1 and PMS2, and loss of all four markers. Ex-
clusive loss of PMS2 expression could be explained by a
Fig. 3 Analysis of MSI status in 166 CRCs and matched normal samples using PNA (left panel) and MNR method (right panel). Representative MSI
analysis results of CRC samples determined as MSI-H or MSS are shown
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PMS2 or MLH1 mutation resulting in intact expression
of MLH1 with abnormal function [24]. Loss of MSH6
together with MLH1 and PMS2 could occur because of
a somatic mutation in MSH6 combined with MLH1
hypermethylation [25]. Rarely, a null pattern has report-
edly been caused by a germline MSH2 mutation together
with somatic MLH1 hypermethylation [26]. The inter-
pretation of these rare MMR expression patterns is chal-
lenging, which limits the application of IHC analysis for
MSI detection. Moreover, the interpretation of IHC re-
sults can be limited by the cut-off value. Although some
studies suggest 5% or 10% cut-off values [27, 28], there
is no consensus on the minimal percentage of nuclear
staining that should be considered as intact expression.
Because slight discordance between IHC and MSI mo-
lecular tests is rather natural [29], our results suggest
that > 5% nuclear staining was the best match to MSI
test results. The challenging interpretation of IHC re-
sults could be due to somatic missense mutations in
sporadic CRCs that can reduce IHC staining without af-
fecting MMR protein expression and thus not cause
pathogenesis [30]. Tissue fixation status, somatic mosai-
cism, or other gene defects that also cause a MSI-H
phenotype also could affect the interpretation of IHC re-
sults [28]. Indeed, there was one case (Case no. 20), de-
termined as MSI-H by other molecular tests, that
showed expression of all four MMR proteins. Therefore,
we suggest that additional molecular tests of MSI status
should be performed in cases with decreased expression
of one or more MMR genes and/or clinicopathologic
features related to the MSI-H subtype.
Several methods using amplicon melting analysis had
been suggested for genotyping and mutation scanning.
The primitive techniques had required a fluorescently, la-
beled primer, and been limited to the detection of muta-
tions residing in the melting domain of the labeled primer.
Taking advantage of a double-stranded DNA dye, Wittwer
et al. reported another amplicon melting analysis method
that did not require any labeled primers. This method was
not limited by the requirement that sequence variants
have to be in the same melting domain [31]. Likewise,
real-time PCR based methods have been developed for
the analysis of various DNA alterations. Here, we evalu-
ated the performance of three MSI detection molecular
tests and found that PNA method can be used as a time-
and cost-efficient molecular test for MSI diagnosis.
Instead of using a set of five marker genes (two mononu-
cleotide repeats and three dinucleotide repeats) recom-
mended by the NCI, PNA method employs a panel of five
marker genes containing quasi-monomorphic mononucle-
otide repeats proposed by Buhard et al. [32]. Many previ-
ous studies have shown that quasi-monomorphic
mononucleotide repeats are far more sensitive than di-
nucleotide repeats in detecting MSI [33–35]. PNA method
adopts a PNA-based real-time PCR sensing strategy that
can be performed by a conventional real-time PCR ma-
chine and requires only a small amount of sample. We
demonstrate that PNA method was capable of detecting a
very small proportion of a mutant gene variant (5%) in a
mixed sample of wild-type and mutant gDNAs, which
complies with the College of American Pathologists guide-
line that molecular tests should be capable of detecting
mutation in specimens with > 5% tumor cell population
[36]. PNA probes enable strong amplification of mutant
and weak amplification of wild type allele in a sample con-
taining wild type and mutant alleles, which guarantees
sensitive detection of mutant variants without an internal
positive control. Since most clinical samples contain both
normal and mutant variants, PNA method shows higher
utilization over previous melting point analysis
methods. As shown in the MNR analysis results of
NR24 and BAT25 in samples containing 20% MSI-H
variants (Fig. 1b), interpretation of data from MNR could
be highly confusing and subjective. This might be due to
artifacts in capillary electrophoresis that appear as smaller,
split, and stutter peaks. Challenging interpretation of
MNR analysis results likely reduces data reproducibility.
On the other hand, PNA method provides data consisting
of clear and sharp melting peaks detected at a specific
melting temperature, which facilitates interpretation of
data for researchers. There are some demerits also in the
PNA method. The procedure for PNA method takes rela-
tively longer than a general real-time PCR protocol for ac-
curacy reasons (requiring ~ 4.5 h), and PNA method
cannot distinguish homozygotes from heterozygotes,
which might not be a critical disadvantage for this method
due to using quasi-monomorphic markers. In terms of
cost-efficiency, the cost for running PNA method is about
three-fifths of that for PCR fragment analysis-based MSI
tests (MNR and NCI methods). Moreover, PNA method
can be performed in a general real-time PCR machine,
which costs only one-fourths of a sequencer required for
PCR fragment analysis. Overall, PNA method has some
advantages over MNR and NCI methods.
The determination of MSI status is critical for the in-
tense lifelong screening of patients with Lynch syndrome
and the appropriate treatment of patients with sporadic
CRCs. Amsterdam criteria (revised to Amsterdam II cri-
teria in 1998) and revised Bethesda criteria are used to
identify HNPCCs, which could lead to the misdiagnosis
of some CRC patients with Lynch syndrome. Therefore,
it is highly recommended that every diagnosed CRC pa-
tient undergo Lynch syndrome screening by IHC and/or
molecular tests. However, Lynch syndrome screening for
every colon cancer patient is not cost-effective. We
therefore propose two possible screening algorithms,
both of which employ screening for MSI using IHC for
PMS2 and MSH6 based on our finding that the
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detection rate of MSI using these two markers was the
same as that using all four markers when the cut-off
value was ≤5% nuclear expression (Additional file 3:
Table S6). In both algorithms, CRC patients are divided
into two groups depending on clinical criteria such as
Amsterdam II or Revised Bethesda criteria. In the first
algorithm, MSI screening is initially performed by IHC
using PMS2 and MSH6 markers, which reduces the cost
by half compared to applying IHC analysis in four MMR
markers. Next, a cost- and time-efficient tool, such as
PNA, is applied to determine MSI presence in CRCs,
which also reduces the cost by three-fifths and time by
half compared to using conventional molecular tests
(Additional file 2: Figure S4). In the second algorithm,
MSI screening is initially performed using PNA and sub-
sequent IHC analysis is performed to identify suspected
gene(s), which could be similarly time- and cost-efficient
as the first algorithm (Additional file 2: Figure S5). How-
ever, a molecular test for MSI analysis should be care-
fully selected since, test results from independent
methods that even use the same MSI markers some-
times show discrepancy. In our cohort, there was a sam-
ple (Case no. 1) that was determined as MSI-L by MNR
method, but as MSI-H by PNA method. In this case,
comparing two results is possible, but deciding which is
correct can be difficult.
Conclusions
In this study, we have evaluated the MSI detection per-
formance of a recently developed PNA method, conven-
tional molecular tests, and immunohistochemistry. Based
on our findings, we suggest that PNA method could be
used as a simple alternative to existing molecular tests.
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